Syndax (SNDX) Q2 2026 earnings review
Operating Leverage Shines as Dual Launches Mature
Syndax delivered a powerful quarter, proving its transition to a commercial-stage powerhouse is sustainable. Q2 2026 total revenue reached $72.8 million (+92% YoY), driven by Revuforj ($54.7M) and Niktimvo collaboration revenue ($18.1M). Most importantly, operating expenses remained essentially flat YoY at $112.8M. This massive operating leverage resulted in the net loss narrowing by 31% YoY to $(49.4)M. With a robust $575 million in cash and both commercial assets annualizing above $200 million, the company is firmly on a stable path to profitability. However, as sequential growth rates naturally decelerate from their initial launch hyper-growth, the narrative will increasingly hinge on upcoming Q4 binary clinical readouts.
🐂 Bull Case
Total revenue grew 92% YoY while total operating expenses only grew 5%. This dramatic decoupling of revenue from costs confirms management's guidance that the company can achieve profitability without needing to raise additional dilutive capital.
Revuforj prescriptions grew 15% QoQ to ~1,500, matching a 12% QoQ net revenue growth. The thesis of extending average treatment duration—driven by patients restarting post-transplant and migrating to earlier lines of therapy—is actively playing out in the data.
🐻 Bear Case
While YoY numbers look explosive, Revuforj's QoQ growth was 12%, and Niktimvo's net revenue growth was just 9%. The initial 'bolus' launch phase is over; achieving multibillion-dollar TAMs now requires flawless execution in label expansions.
The stock's next major leg up is heavily dependent on Phase 2 Niktimvo data in idiopathic pulmonary fibrosis (IPF) and frontline cGVHD due in Q4 2026. A miss here would instantly reset long-term valuation models.
⚖️ Verdict: 🟢
Bullish. Syndax is executing perfectly on the fundamentals: growing sales, holding the line on expenses, and maintaining a fortress balance sheet. The commercial story is de-risked; the upside lies entirely in the pipeline.
Key Themes
Revuforj Post-Transplant Duration Expands
Revuforj's net revenue of $54.7M (+12% QoQ) and prescription growth of 15% (to ~1,500) show stable, compounding momentum. Over 30% of this revenue is now driven by the NPM1 segment. More importantly, the 'transplant and return' thesis is working: an increasing average treatment duration is being fueled by a growing pool of patients receiving Revuforj for an extended period post-transplant.
Niktimvo's Highly Profitable Base
Niktimvo generated $60.3M in net revenue (reported by partner Incyte), yielding $18.1M in collaboration revenue for Syndax. This represents a 50% share of net commercial profit. The 67% YoY growth underscores the benefits of Niktimvo's unique mechanism in chronic GVHD and provides a durable, high-margin cash stream to fund the rest of the pipeline.
Cost Discipline Accelerating Profitability
Management continues to enforce fierce cost discipline. Q2 2026 Selling, General and Administrative (SG&A) expenses actually reversed, dropping to $41.5M from $43.8M a year ago due to the roll-off of initial launch costs. This fixed operating expense base ensures that every incremental dollar of gross profit falls directly to the bottom line.
Sequential Growth Rates are Maturing
While management touts 'blockbuster trajectories', specific data points show a decelerating trend in sequential growth. Incyte reported Niktimvo net revenue grew just 9% QoQ (to $60.3M), and Revuforj grew 12% QoQ. These are healthy numbers, but they contradict the narrative of perpetual hyper-growth. Further acceleration will require breaking into new lines of therapy rather than just riding the initial launch wave.
Execution Risk in Frontline Market Pivot
The company's primary strategy to reach a $5B+ TAM is moving Revuforj into frontline AML (EVOLVE-2, REVEAL-ND, RAVEN trials). This requires changing the standard of care away from established intensive chemotherapy regimes. While trial enrollment is strong, any hiccups in these Phase 3 readouts will severely cap Revuforj's peak sales potential.
Strategic Pipeline Pivot: SNDX-4321 and SNDX-62122
Syndax is officially planning for life beyond its current commercial indications. The introduction of SNDX-4321 (a novel, mutant-selective allosteric EGFR inhibitor for NSCLC) and SNDX-62122 (a next-gen menin inhibitor for myelofibrosis) shifts the company narrative from a purely hematology-focused commercial entity to a broader oncology platform. INDs are expected by late 2026/2027.
Other KPIs
Accelerating significantly from $394.1M at the end of FY2025. This provides an undisputed runway to reach organic profitability without tapping equity markets, heavily de-risking the balance sheet.
Stable YoY increase from $62.2M in Q2 2025. The slight uptick is strictly tied to advancing frontline trials evaluating revumenib in combination with standard-of-care agents.
Guidance
Stable. The company maintained its guidance of $400M (excluding ~$50M in stock-based compensation). With H1 2026 OpEx at $211.8M, this implies a completely flat run rate of ~$100M per quarter for the remainder of the year.
Management explicitly reiterated that current cash, combined with product and collaboration revenue, will enable the company to reach profitability without additional capital raises.
Key Questions
Niktimvo Sequential Growth Dynamics
Niktimvo's net revenue growth decelerated to 9% QoQ. Is this a function of natural patient attrition in the later-line 3L+ setting catching up with new patient starts, or are there seasonal/inventory dynamics at play?
Gross-to-Net Adjustments for Revuforj
Revuforj revenue grew 12% QoQ against a 15% increase in prescriptions. Does this 300 basis point spread indicate a slight increase in gross-to-net adjustments or a shift toward government payer mix?
SNDX-4321 Differentiation
Regarding the new allosteric EGFR inhibitor, how does the preclinical profile of SNDX-4321 differentiate from existing ATP-site directed inhibitors like Tagrisso, specifically concerning combination tolerability ('double drugging')?
MAXPIRe (IPF) Trial Sensitivity
As we approach the Q4 readout for the Phase 2 MAXPIRe trial of axatilimab in IPF, what specific magnitude of FVC decline reduction will management view as a definitive 'go' decision for Phase 3?